One Ascent Financial Services LLC Cellectis S.A. Transaction History

One Ascent Financial Services LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$11.94 - $16.09 $146,790 - $197,810	-12,294 Closed	0 $0
Q1 2021 Apr 27, 2021	BUY	$18.19 - $33.25 $22,082 - $40,365	1,214 Added 10.96%	12,294 $248,000
Q4 2020 Feb 08, 2021	SELL	$15.87 - $31.64 $199,057 - $396,860	-12,543 Reduced 53.1%	11,080 $300,000
Q4 2020 Jan 13, 2021	BUY	$15.87 - $31.64 $27,645 - $55,116	1,742 Added 7.96%	23,623 $639,000
Q3 2020 Nov 02, 2020	BUY	$15.7 - $20.84 $69,284 - $91,966	4,413 Added 25.26%	21,881 $405,000
Q2 2020 Jul 21, 2020	BUY	$8.21 - $21.02 $2,816 - $7,209	343 Added 2.0%	17,468 $311,000
Q1 2020 Apr 14, 2020	BUY	$7.81 - $18.82 $14,190 - $34,195	1,817 Added 11.87%	17,125 $158,000
Q4 2019 Feb 11, 2020	BUY	$9.73 - $19.31 $148,946 - $295,597	15,308 New	15,308 $262,000
Q3 2019 Nov 15, 2019	SELL	$10.15 - $16.89 $167,140 - $278,127	-16,467 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$14.6 - $20.6 $240,418 - $339,220	16,467 New	16,467 $257,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of One Ascent Financial Services LLC, based on Form 13F filings with the SEC.

Stay updated on One Ascent Financial Services LLC with notifications on news.